<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10175130</article-id><article-id pub-id-type="pmcid-ver">PMC10175130.1</article-id><article-id pub-id-type="pmcaid">10175130</article-id><article-id pub-id-type="pmcaiid">10175130</article-id><article-id pub-id-type="manuscript-id">NIHMS1877516</article-id><article-id pub-id-type="pmid">36710474</article-id><article-id pub-id-type="doi">10.1111/add.16147</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1877516</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1877516</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>COMPREHENSIVE NEEDLE AND SYRINGE PROGRAM AND OPIOID AGONIST THERAPY REDUCE HIV AND HEPATITIS C VIRUS ACQUISITION AMONG PEOPLE WHO INJECT DRUGS IN DIFFERENT SETTINGS: A POOLED ANALYSIS OF EMULATED TRIALS</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>van Santen</surname><given-names initials="DK">Daniela K.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lodi</surname><given-names initials="S">Sara</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dietze</surname><given-names initials="P">Paul</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van den Boom</surname><given-names initials="W">Wijnand</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayashi</surname><given-names initials="K">Kanna</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="H">Huiru</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="Z">Zishan</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maher</surname><given-names initials="L">Lisa</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hickman</surname><given-names initials="M">Matthew</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boyd</surname><given-names initials="A">Anders</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prins</surname><given-names initials="M">Maria</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A10" ref-type="aff">10</xref><xref rid="A11" ref-type="aff">11</xref></contrib></contrib-group><aff id="A1"><label>1.</label>Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands</aff><aff id="A2"><label>2.</label>Department of Disease Elimination, Burnet Institute, Melbourne, Australia</aff><aff id="A3"><label>3.</label>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia</aff><aff id="A4"><label>4.</label>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA</aff><aff id="A5"><label>5.</label>British Columbia Centre on Substance Use, Vancouver, Canada</aff><aff id="A6"><label>6.</label>Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada</aff><aff id="A7"><label>7.</label>The Kirby Institute for Infection and Immunity, Faculty of Medicine, UNSW Sydney, Sydney, Australia</aff><aff id="A8"><label>8.</label>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK</aff><aff id="A9"><label>9.</label>Stichting HIV Monitoring, Amsterdam, The Netherlands</aff><aff id="A10"><label>10.</label>Amsterdam Institute for Infection and Immunity (AII), Amsterdam, The Netherlands</aff><aff id="A11"><label>11.</label>Amsterdam Public Health Research Institute (APH), Amsterdam, The Netherlands</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2">Daniela van Santen: Conceptualization; writing&#8212;original draft; preparation data curation; formal analysis; funding acquisition; methodology; project administration; visualization. Anders Boyd: Supervision; methodology; writing&#8212;review and editing. Lisa Maher: Writing&#8212;review and editing. Matthew Hickman: Writing&#8212;review and editing. Sara Lodi: Methodology; supervision; writing&#8212;review and editing. Maria Prins: Conceptualization; funding acquisition; supervision; writing&#8212;review and editing. Wijnand van den Boom: Resources; data curation; writing&#8212;review and editing. Paul Dietze: Resources; writing&#8212;review and editing. Kanna Hayashi: Resources; writing&#8212;review and editing. Huiru Dong: Resources; data curation; formal analysis; writing&#8212;review and editing. Zishan Cui: Resources; data curation; formal analysis; writing&#8212;review and editing.</p></fn><corresp id="CR1">Correspondence: Daniela K. van Santen, Public Health Service of Amsterdam (GGD Amsterdam), Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands., <email>dvsanten@ggd.amsterdam.nl</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P45">DECLARATION OF INTERESTS</p><p id="P46">None of the other authors had any conflicts to declare related to this study.</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2023</year></pub-date><volume>118</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">435616</issue-id><fpage>1116</fpage><lpage>1126</lpage><pub-history><event event-type="nihms-submitted"><date><day>24</day><month>02</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1877516.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and Aims</title><p id="P3">Although the Netherlands, Canada and Australia were early adopters of harm reduction for people who inject drugs (PWID), their respective HIV and hepatitis C (HCV) epidemics differ. We measured the pooled effect of needle and syringe program (NSP) and opioid agonist therapy (OAT) participation on HIV and HCV incidence in these settings.</p></sec><sec id="S2"><title>Design</title><p id="P4">For each cohort, we emulated the design and statistical analysis of a target trial using observational data.</p></sec><sec id="S3"><title>Setting and Participants</title><p id="P5">We included PWID at risk of HIV or HCV infection from the Amsterdam Cohort Studies (1985&#8211;2013), Vancouver Injection Drug Users Study (1997&#8211;2009) and Melbourne Injecting Drug User Cohort Study (SuperMIX) (2010&#8211;2021).</p></sec><sec id="S4"><title>Measurements</title><p id="P6">Separately for each infection and cohort (only HCV in SuperMIX), marginal structural models were used to compare the effect of comprehensive (on OAT and 100% NSP coverage or on OAT only if no recent injection drug use) versus no/partial NSP/OAT (no OAT and/or &lt;100% NSP coverage) participation. Pooled hazard ratios (HR) and 95% CI were calculated using random-effects meta-analysis.</p></sec><sec id="S5"><title>Findings</title><p id="P7">We observed 94 HIV seroconversions and 81 HCV seroconversions among 2023 and 430 participants, respectively. Comprehensive NSP/OAT led to a 41% lower risk of HIV acquisition (pooled HR = 0.59, 95% CI = 0.36&#8211;0.96) and a 76% lower risk of HCV acquisition (pooled HR = 0.24, 95% CI = 0.11&#8211;0.51), compared with no/partial NSP/OAT, with little heterogeneity between studies for both infections (I2 = 0%).</p></sec><sec id="S6"><title>Conclusions</title><p id="P8">In the Netherlands, Canada and Australia, comprehensive needle and syringe program and opioid agonist therapy participation appears to substantially reduce HIV and hepatitis C acquisition compared with no or partial needle and syringe program/opioid agonist therapy participation. These findings from an emulated trial design reinforce the critical role of comprehensive access to harm reduction in optimizing infection prevention for people who inject drugs.</p></sec></abstract><kwd-group><kwd>Emulated trial</kwd><kwd>harm reduction programs</kwd><kwd>hepatitis C virus</kwd><kwd>HIV</kwd><kwd>needle and syringe programs</kwd><kwd>opioid agonist therapy</kwd><kwd>people who inject drugs</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>